A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma [LINKER-MM5] (NCT07222761)

A study to compare linvoseltamab monotherapy and linvoseltamab + carfilzomib combination therapy with standard-of-care combination regimens in participants with relapsed/refractory multiple myeloma (RRMM).

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Andrew Spencer

Key inclusion data

MUST HAVE: Received at least 1 but not more than 3 prior lines of therapy, which must have included treatment with lenalidomide and either a PI or anti-CD38 antibody. Measurable relapsed disease. CANNOT HAVE: Diagnosis of plasma cell leukemia, Waldenstrom macroglobulinemia, or POEMS syndrome. Known CNS involvement including meningeal involvement. Another malignany other than MM that is progressive or requires treatment (excluding: nonmelanoma skin cancer, localised thyroid cancer, low risk early stage prostate adenocarcinoma). History of myelodysplastic syndrome, neurodegenerative condition, PML or CNS movement disorder or any uncontrolled psychiatric illnesses (within 12 months).